

## General Information

Name: Dr. rer. nat. Annika Müller (née Scheffold)  
Date of Birth: 28.09.1985  
Gender: Female  
Address: Department of Internal Medicine III, Ulm University  
Albert-Einstein-Allee 23, 89081 Ulm, Germany  
Phone: +49 731 500 45971  
E-Mail: [annika.scheffold@uni-ulm.de](mailto:annika.scheffold@uni-ulm.de)  
Current Position: Post doctoral Researcher

## Academic Education

2006-2011 Studies of Biology, Johannes Gutenberg University of Mainz

## Academic Degrees

2015 Dr. rer. nat. (Ph.D): University of Ulm, Max-Planck Research Group for Stem Cell Ageing, Prof. Dr. K.L. Rudolph  
2011 Diploma thesis at Ulm University, supervisor: Prof. Dr. K.L. Rudolph

## Professional Experience

Since 2015 Post-doctoral Fellow, Research Group of Prof. Dr. Stephan Stilgenbauer, Department of Internal Medicine III, Ulm University

## Miscellaneous

### Awards and Honors:

2018-2019 Hertha-Nathorff Funding for Postdoctoral Researchers, Ulm University  
2018/2019 „Gilead Förderprogramm Onkologie“  
2017 Travel grant of Gilead Sciences for the DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie)  
2017-2018 Intramural Funding Program, University of Ulm (Baustein-Programm)  
2017 Abstract Achievement Award, American Society of Hematology 2017  
2016 Abstract Achievement Award, American Society of Hematology 2016

## Publications

1. [Scheffold A](#), Baig AH, Chen Z, von Löhneysen SE, Becker F, Morita Y, Avila AI, Groth M, Lechel A, Schmid F, Kraus J, Kestler HA, Stilgenbauer S, Philipp M, Burkhalter MD. Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. *Leukemia*. 2019 Nov 14. [Epub ahead of print]
2. [Scheffold A\\*](#), Jebaraj BMC\*, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. IGF1R as druggable target mediating PI3K- $\delta$  inhibitor resistance in a murine model of chronic lymphocytic leukemia. *Blood*. 2019;134(6):534-547. \*Equal contribution
3. Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, [Scheffold A](#), Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. *Leukemia*. 2019 Mar 25 [Epub ahead of print]
4. [Scheffold A\\*](#), Hanna BS\*, Roessner PM\*, Jebaraj BMC, Demerdash Y, Öztürk S, Lichter P, Stilgenbauer S, Seiffert M. PI3K $\delta$  inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. *Leukemia*. 2019;33(6):1427-38. \*Equal contribution
5. Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, [Scheffold A](#), Villalobos-Ortiz M, Boldrin E, Zingrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler

- HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. **Cell Death Dis.** 2019;10(8):571.
6. Armacki M, Trugenberger AK, Ellwanger AK, Eiseler T, Schwerdt C, Bettac L, Langgartner D, Azoitei N, Halbgebauer R, Groß R, Barth T, Lechel A, Walter BM, Kraus JM, Wiegrefte C, Grimm J, Scheffold A, Schneider MR, Peuker K, Zeißig S, Britsch S, Rose-John S, Vettorazzi S, Wolf E, Tannapfel A, Steinestel K, Reber SO, Walther P, Kestler HA, Radermacher P, Barth TF, Huber-Lang M, Kleger A, Seufferlein T. Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure. **J Clin Invest.** 2018;128(11):5056-72.
  7. Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: Targeting BCL2 in Hematological Cancers. **Recent Results Cancer Res.** 2018;212:215-42.
  8. Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. **Leuk Lymphoma.** 2018;59(7):1614-23.
  9. Scheffold A\*, Jebaraj BM\*, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, and Stilgenbauer S. Impact of telomere length and outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. **Br J Hematol.** 2017;179(2):342-46. \* Equal contribution
  10. Scheffold A, Holtman IR, Dieni S, Brouwer N, Katz SF, Jebaraj BM, Kahle PJ, Hengerer B, Lechel A, Stilgenbauer S, Boddeke E, Eggen BJ, Rudolph KL, and Biber K. Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. **Acta Neuropathol Commun.** 2016;4(1):87.